Testing a new combination therapy for older adults with aggressive B-cell lymphoma

Plain-English translation of NCT06765317 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This study is testing whether , a newer cancer medication, works well when combined with other proven treatments for diffuse large B-cell lymphoma (an aggressive type of blood cancer). The combination includes the medication along with three other standard chemotherapy drugs. Researchers want to see if this approach is effective and causes fewer or milder side effects, especially in older adults.

Current standard treatments for this type of lymphoma can be hard on older adults' bodies. This trial is testing whether using this newer medication alongside gentler doses of standard chemotherapy might give better results with fewer serious side effects for older patients.

Do you qualify?

You likely qualify if…

you are 65 to 79 years old and have been assessed as physically unfit or frail, OR you are 80 years or older (any fitness level)
you have been diagnosed with diffuse large B-cell lymphoma, high-grade B-cell lymphoma, or transformed lymphoma confirmed by a biopsy
you have never received systemic chemotherapy or other anti-lymphoma treatments before (except short-term steroids)
your cancer is stage 2 (with a large tumor), stage 3, or stage 4
your heart is strong enough for chemotherapy, with an ejection fraction of at least 45%
you have at least one measurable tumor visible on CT or MRI scans

You likely don't qualify if…

you have a positive HIV test (unless you are stable on HIV medication with a CD4 count above 200 and undetectable viral load)
you have severely weakened bone marrow function or organ function (kidney, liver, or heart problems) that doesn't meet study requirements
you are able to have children and not willing to use reliable contraception during and for months after treatment
you have already received systemic anti-lymphoma therapy in the past
your tumor cannot be measured on imaging or is too small to track

What participation looks like

You would receive two starting cycles of the medication combination, followed by an imaging scan to see how well the treatment is working. Based on your scan results, you would then receive either 4 or 6 additional cycles of the full or modified treatment combination. This means regular visits to the cancer center for infusions and blood tests over several months, with close monitoring of how you're tolerating the medications and how your lymphoma is responding.

AI-generated summary from trial data · Jul 3, 2026 · Not medical advice

Trial locations(8 sites)

United States

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

Hackensack Meridian Health (Data collection only), Hackensack, New Jersey

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey

Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities), Commack, New York